Prosecution Insights
Last updated: November 04, 2026
Application No. 19/227,467

METHOD FOR CONSTRUCTING HEPATIC PROGENITOR CELL-LIKE CELL BANK, CELL LINES PREPARED THEREFROM AND APPLICATION THEREOF

Non-Final OA §103§DOUBLEPATENT
Filed
Jun 04, 2025
Priority
Jul 11, 2019 — CN 201910623436.9 +2 more
Examiner
VIJAYARAGHAVAN, JAGAMYA NMN
Art Unit
1633
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Shanghai Cryowise Medical Technology Co. Ltd.
OA Round
1 (Non-Final)
62%
Grant Probability
Moderate
1-2
OA Rounds
2y 3m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 62% of resolved cases
62%
Career Allowance Rate
26 granted / 42 resolved
+1.9% vs TC avg
Strong +51% interview lift
Without
With
+51.4%
Interview Lift
resolved cases with interview
Typical timeline
3y 9m
Avg Prosecution
48 currently pending
Career history
97
Total Applications
across all art units

Statute-Specific Performance

§101
5.6%
-34.4% vs TC avg
§103
31.8%
-8.2% vs TC avg
§102
14.8%
-25.2% vs TC avg
§112
32.8%
-7.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 42 resolved cases

Office Action

§103 §DOUBLEPATENT
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority The instant application is a 371 of PCT/CN2020/086659. Acknowledgment is made of applicant’s claim for foreign priority under 35 U.S.C. 119 (a)-(d) to Chinese application 201910623436.9, filed Jul. 11, 2019. A certified copy is present in Application US17/622,838. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1-3 are rejected under 35 U.S.C. 103 as being unpatentable over Burkard et al Xenobiotica. 2012 Oct (hereinafter “Burkard”, See PTO-892) in view of Wu et al Cell Res. 2017 May (hereinafter “Wu”, See PTO-892), Aznan et al Oncol Lett. 2018 Jul (hereinafter “Aznan”, See PTO-892) Godoy et al Arch Toxicol. 2016 Oct (hereinafter “Godoy”, See PTO-892), Alverez-Salas et al (Proc. Natl. Acad. Sci. U.S.A.; 1998; hereinafter “Alverez-Salas;” See PTO-892) and Tsuruga et al (Cell Transplant. 2008 Sep; hereinafter “Tsuruga;” See PTO-892). Regarding claim 1 S1: Wu teaches isolation of primary hepatocytes from mice by seeding at a density of 2 × 10 4 cells/cm2 for 1 week (See Wu Supplemental at p. 2). However, Wu does not teach culture of human primary hepatocytes and cryopreservation of the primary hepatocytes as required by S1. However, Godoy teaches mice and human primary hepatocytes can be cultured using similar method. (See Godoy page 2514, col. 2, Materials and Methods section). Further Burkard teaches cryopreservation of primary hepatocytes. (See Burkard p. 941, col. 1, 2nd paragraph). As such, culturing cells and cryopreservation are all routine in the art of mammalian cell culture. It would have been obvious to a person of ordinary skill in the art to apply known hepatocyte culture techniques to human primary hepatocytes and to cryopreserve the cultured cells, as taught by Burkard, to preserve the cell population for subsequent use. As such, the use of such techniques in human hepatocyte primary cells would have constituted predictable application of a known hepatocyte culture technique in view of Godoy. Regarding claim 1 S2: Burkhard teaches passaging cells at 80% confluence. (See Burkard p. 941, col. 1, 2nd paragraph). This falls within the claimed range. However, as such it would be obvious for a skilled artisan to arrive at the steps of S2 in view of Burkard. It is pointed out that selecting a suitable confluence for passaging would have been a routine adjustment of a recognized cell-culture parameter to facilitate cell maintenance and propagation. Regarding claim 1 S3: Burkard does not specifically teach passaging cells before transduction as required by the claim (See Burkhard Burkard p. 941, col. 1, line 2). However, subculturing cells before transduction is routine in the art of mammalian cell culture, as shown in Aznan. Specifically, Aznan teaches, it is desirable to use hepatocytes with less than 16 passages for efficient transduction. (See Aznan page 79, col. 2, 2nd paragraph). In view of these teachings, one of ordinary skill in the art would have had a reason to select an appropriate passage stage before transduction and use a suitable medium before transduction to facilitate introduction of a foreign genetic material. As such adjusting the passage number is considered a routinely optimizable variable and absent any teaching of criticality by the Applicant concerning the subculturing of hepatocyte progenitor cells, it would be obvious that one of ordinary skill in the art would recognize the subculture of hepatocytes is routine and optimizable variable. As indicated above, seeding densities are optimizable and are not obvious for the reasons stated above. Further, as indicated above, Burkard teaches viral transduction. Additionally, Alvarez-Salas teaches that HPV16 E6/E7 genes are associated with efficient immortalization of a broad spectrum of cell types. (See Alvarez-Salas Abstract). Further Tsuruga taught immortalization of human hepatocytes by the introduction of HPV16 E6/E7 and hTERT. (See Tsuruga Abstract). It is also noted that Tsuruga taught lentiviral transduction in the presence of polybrene. (See Tsuruga p. 1084, col.2, para 3). In view of Tsuruga’s disclosure, one of ordinary skill in the art seeking to establish an expandable population of human liver-derived cells would have had reason to consider the disclosed E6/E7 based immortalization approach. As such Tsuruga and Alvarez-Salas further support the known use of E6/E7 in cellular immortalization and its application in human liver-derived cells. It is also noted that Tsuruga taught the use of polybrene solution in lentiviral transduction. (See Tsuruga p.1084, col.3 para 3). Regarding claim 1 S4-S5: Burkard taught subculturing the transduced cell. Burkard does not explicitly teach passage number of 2 or 3. It is known, as evidenced by Neuhuber et al (Exp Hematol. 2008 Sep, p.5, 2nd paragraph) that passage number is dependent on original seeding density, and population doubling time and is readily optimizable. As such, the split ratios and passage numbers would be readily optimizable for each cell type for a skilled artisan in the field of mammalian cell culture. As indicated above, differences in optimizable parameters such as passage numbers will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such parameter is critical. "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." (See MPEP 2144.05). In the current claim, it is unobvious to optimize passage numbers. It would have been obvious to one of ordinary skill in the art at the time of the invention to combine the teachings of Burkard, Wu, Godoy, Aznan, Alvarez-Salas, and Tsuruga to obtain the claimed method of culturing, passaging, cryopreserving, transducing, selecting, and banking human hepatic cells. The references collectively teach hepatocyte culture and cryopreservation, relevant culture and passage conditions, transduction and selection techniques, and the use of HPV-16 E6/E7 together with hTERT to immortalize human hepatocytes. A person of ordinary skill in the art would have been motivated to apply these known techniques and optimize culture parameters to obtain a suitable cell population for expansion and banking, with a reasonable expectation of success to the extent supported by the teachings of the prior art. Accordingly, the claimed method would have been obvious absent evidence of criticality, unexpected results, or other persuasive evidence of nonobviousness. Regarding claim 2: The teachings of Burkard in view of Wu are set forth above. Burkard taught that culturing or expansion of cells before cryopreservation. For example, Burkard taught “Stage one is to grow the cells to the first “Master Cell Bank” (MCB1) and then cryopreserve them at 12 million cells per vial. “ (See Burkard p. 940, col.1, para 1). It would have been obvious for a person of ordinary skill in the art to subculture the primary hepatocytes for 1 or 2 subcultures to obtain sufficient cells for cryopreservation. Absent evidence of unexpected results, selecting one to two subcultures is a known optimizable result effective variable. Regarding claim 3: Burkard teaches 3D hepatocyte culture using polystyrene scaffolds (See Burkard p. 940, col. 1, 3rd paragraph), using cells prepared from the cell bank. Burkard further teaches screening hepatotoxicity using the cells from the cell bank (See Burkard p. 940, col.1, 4th paragraph, col. 2, 1st paragraph, p. 943, col.1, 1st paragraph) Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-3 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-3 of U.S. Patent No. 12351828 (hereinafter ‘828 Patent). Although the claims at issue are not identical, they are not patentably distinct from each other for the reasons set forth below. Regarding claim 1: ‘838 Patent teaches the claimed method of providing human primary hepatocytes and culturing them as required by the instant claims. Claims 1 is provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claim 13 of U.S. Application No. 17/631,474 (hereinafter ‘474 Application). Although the claims at issue are not identical, they are not patentably distinct from each other for the reasons set forth below. Regarding claim 1: Claim 13 of U.S. Application No. 17/631,474 teaches the claimed method of providing human primary hepatocytes and culturing them as required by the instant claims. Claim Objection Claim 3 requires a method of preparing the hepatic progenitor cell bank according to claim 1, the method comprising: constructing an in vitro three-dimensional hepatocyte model; and testing a specific hepatotoxicity of a drug by the in vitro three-dimensional hepatocyte model. The preamble defines a method of preparing the hepatic progenitor cell bank of claim 1, but the recited steps concern model construction and testing. This creates a potential mismatch between the stated purpose and the operative steps. Appropriate correction is required. Conclusion No claim is allowed. No claim is free of the prior art. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JAGAMYA VIJAYARAGHAVAN whose telephone number is (703)756-5934. The examiner can normally be reached 9:00a-5:00p. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Christopher M. Babic can be reached on 571-272-8507. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JAGAMYA NMN VIJAYARAGHAVAN/Examiner, Art Unit 1633 /EVELYN Y PYLA/Primary Examiner, Art Unit 1633
Read full office action

Prosecution Timeline

Jun 04, 2025
Application Filed
Jan 08, 2026
Examiner Interview Summary
Oct 20, 2026
Non-Final Rejection mailed — §103, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12760288
METHOD FOR TARGETED MODIFICATION OF SEQUENCE OF PLANT GENOME
4y 5m to grant Granted Oct 13, 2026
Patent 12709733
CELL CULTURE MEDIA
4y 3m to grant Granted Aug 18, 2026
Patent 12681006
METHODS OF GENERATING HUMAN ENDOMETRIAL STROMAL FIBROBLASTS AND THREE-DIMENSIONAL MULTI-LAYERED HUMAN ENDOMETRIAL TISSUE COMPOSITIONS
4y 2m to grant Granted Jul 14, 2026
Patent 12667621
RNA FORMULATIONS SUITABLE FOR THERAPY
4y 6m to grant Granted Jun 30, 2026
Patent 12637700
NOVEL METABOLIC PATHWAY FOR PRODUCING ITACONIC ACID AND METHOD FOR PRODUCING ITACONIC ACID USING SAME
2y 5m to grant Granted May 26, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
62%
Grant Probability
99%
With Interview (+51.4%)
3y 9m (~2y 3m remaining)
Median Time to Grant
Low
PTA Risk
Based on 42 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month